A research collaboration was established in 2007 between the Belfer Institute of Applied Cancer Science and Merck & Co., Inc. to discover new cancer targets, define the biological context of those targets, and co-develop novel cancer therapeutics to reach those targets. In December 2010 the Belfer Institute and Merck agreed to extend the collaboration for two more years.
In 2010, the Belfer Institute of Applied Cancer Science and Sanofi-Aventis also established a cancer research alliance focused on identification and validation of novel cancer targets, discovery of novel therapeutics and associated biomarkers.
In the News
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.